Companhia de Saneamento Básico do Estado de São Paulo ADR (SBS)
Sabesp (SBS) is on the Move, Here's Why the Trend Could be Sustainable
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (SBS) Q4 2024 Earnings Call Transcript
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:SBS ) Q4 2024 Earnings Conference Call March 25, 2025 12:00 PM ET Company Participants Thiago Levy - Investor Relations Director Daniel Szlak - Chief Financial Officer and Investor Relations Officer Carlos Augusto Leone Piani - Chief Executive Officer Operator Good morning and welcome to SABESP Fourth Quarter of 2024 Earnings Presentation. With us here today are Carlos Piani, CEO; Daniel Szlak, CFO; and Thiago Levy, Investor Relations.
Recent Price Trend in Sabesp (SBS) is Your Friend, Here's Why
Sabesp (SBS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Sabesp (SBS) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Utilities Stocks Lagging Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) This Year?
Here is how Sabesp (SBS) and Telecom Italia (TIIAY) have performed compared to their sector so far this year.
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that an independent IIT in the U.S. to evaluate the efficacy and safety of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of short bowel syndrome with intestinal failure (SBS-IF) in adults has begun. An overview of the study can be viewed on the ClinicalTrials.gov website.
Sabesp Q3: Good Result, But Macro Scenario Continues To Leave Me Skeptical
Recommend holding Sabesp shares post-3Q24 results due to good trends, but valuation lacks safety margin amid Brazilian economic instability. Net revenues rose 9.6% y/y to $987 million, driven by tariff adjustments and privatization impacts on corporate accounting. Operating costs fell 3.1% y/y, with a strong EBITDA margin of 59.9%, and net income increased 43.7% y/y to $201 million.
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q3 2024 Earnings Call Transcript
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Luiz Tiberio - IR Superintendent Carlos Piani - CEO Daniel Szlak - Financial Director, Investor Relations Conference Call Participants Luiz Tiberio Good morning, everyone. My name is Luiz Roberto Tiberio.
Sabesp (SBS) Is a Great Choice for 'Trend' Investors, Here's Why
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.
Here's Why Momentum in Sabesp (SBS) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
